SecBot SecBot
8-K ·Filed Nov 4, 2026

COR

Cencora, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed12d 12h ago SEC0001140859-26-000040
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor the Q1 FY2027 earnings release for the first full-quarter results under the new segment structure and for any updates on the strategic alternatives for the Other segment businesses.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$354.00
T+0 close · Nov 4, 2026 · via day close
Latest settled
−1.16%
T+5 · $349.88
Vs SPY
−0.25%
α at T+5
Next horizon
T+20
in 16d
  1. T+0 · Nov 4 $354.00entry
  2. T+1 · 12d ago −4.05%α +0.36% · $339.68
  3. T+5 · 6d ago −1.16%α −0.25% · $349.88
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cencora filed an 8-K to disclose a restructuring of its operating model and a new reportable segment structure effective Q1 FY2027. The filing includes unaudited revised segment revenue and operating income data for FY2025 and FY2026 under the new segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. This is a routine disclosure of a structural change with no new financial guidance or material impact on overall results.

Key Facts

  • Cencora restructured its operating model and reorganized business components within U.S. Healthcare Solutions and International Healthcare Solutions reportable segments.
  • New reporting structure effective Q1 FY2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
  • Other segment includes businesses under strategic review: MWI Animal Health, Profarma, and other components of PharmaLex.
  • FY2026 total revenue was $337.4 billion, up 5.0% from FY2025 total revenue of $321.3 billion.
  • FY2026 total segment operating income was $4.81 billion, up 14.0% from FY2025 total segment operating income of $4.22 billion.
  • Pharmaceutical Distribution and Services FY2026 operating income margin was 0.96% vs 0.92% in FY2025.
  • Specialty Pharmaceutical and Provider Services FY2026 operating income margin was 3.73% vs 3.22% in FY2025.

Financial Impact

No new financial guidance or material change to overall results; segment reclassification only.

revenueoperating income

Risk Factors

  • The Other segment, which includes businesses under strategic review, had an operating income margin of 4.50% in FY2026, down from 4.31% in FY2025; any divestiture or impairment could affect future results.
  • Restructuring execution risk may temporarily impact segment-level performance in the near term.

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
70% bullish (20 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140859-26-000040
Document: abc-20261104.htm0001140859-26-000040
Document: 0001140859-26-000040-index-headers.html0001140859-26-000040
Document: 0001140859-26-000040-index.html0001140859-26-000040
Document: 0001140859-26-000040.txt0001140859-26-000040

Track record

12 reports on COR

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +6.03% at T+20 after the Aug 5, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 4, 202612d ago 8-K Neutral 2/10 Viewing Entry $354.00 to $339.68 Now $356.94 +0.83% ▼ −4.05% +0.36% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $354.00 to $339.68 Now $356.94 +0.83% ▼ −4.05% +0.36% vs SPY
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $340.43 to $338.48 Now $356.94 +4.85% ▼ −0.57% +0.61% vs SPY
  4. Oct 20, 202627d ago Institutional Cluster Mixed 3/10 Entry $340.43 to $338.48 Now $356.94 +4.85% ▼ −0.57% +0.61% vs SPY
  5. Sep 25, 20267w ago 8-K Neutral 2/10 Entry $306.92 to $303.81 Now $356.94 +16.30% ▼ −1.01% −0.27% vs SPY
  6. Aug 21, 202612w ago Institutional Cluster Mixed 6/10 Entry $318.04 to $323.77 Now $356.94 +12.23% ▲ +1.80% +2.10% vs SPY
  7. Aug 5, 202614w ago 8-K Neutral 3/10 Entry $317.22 to $325.01 Now $356.94 +12.52% ▲ +2.46% +2.62% vs SPY
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $317.22 to $325.01 Now $356.94 +12.52% ▲ +2.46% +2.62% vs SPY
  9. Jun 15, 202622w ago 8-K Neutral 2/10 Entry $281.46 to $277.09 Now $356.94 +26.82% ▼ −1.55% −0.30% vs SPY
  10. May 29, 202624w ago 8-K Neutral 3/10 Entry $264.69 to $264.84 Now $356.94 +34.85% ▲ +0.06% −0.10% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026